Menu Back toSESSION-5-Data-Collection-and-Utilization-for-Gene-Therapy-Products-after-Launch

4th DIA Cell and Gene Therapy Products Symposium in Japan

All prices are exclusive of 10% Japanese consumption tax

SESSION 5 - Data Collection and Utilization for Gene Therapy Products after Launch

Session Chair(s)

Sumimasa  Nagai, MD, PhD

Sumimasa Nagai, MD, PhD

  • Institute for Advancement of Clinical and Translational Science(iACT)
  • Kyoto University Hospital, Japan
In 2019, two gene therapy products have been approved as regenerative medicine in Japan, marking the first year of Japan’s gene therapy commercialization. Gene therapy products are the products that highly require continuous evaluation of efficacy and safety even after the launch in the market. Given the circumstances where more gene therapy products are expected to be approved in the future, pharmaceutical companies are taking an increasing interest in procedures for relevant data collection, such as scheme and contents and how to utilize them. In this session, the specialists will explain the current situation surrounding the ongoing data collection for the two gene therapies approved this year. In addition, we will discuss how to plan and prepare appropriate data collection measures for future gene therapy products.


Yoshiko  Atsuta, MD, PhD

Hematopoietic Cell Transplantation and Cellular Therapy Registry in Japan

Yoshiko Atsuta, MD, PhD

  • Head
  • The Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Japan
Mitsuaki  Chujo, PhD

Post Marketing Strategies of Novel Gene Therapy Product Collategene

Mitsuaki Chujo, PhD

  • Director, Pharmacovigilance Department
  • AnGes, Inc., Japan

Contact us

Please contact DIA Japan for further information.

Send Email